Translating these observations to the field of LTx suggests that a decreased suppression of Th-1 immune responses in patients genotyped with the risk variant of PTPN22 could contribute to autoimmunity and the pathogenesis of BOS development. The gene discussed is PTPN22; the disease is Buschke-Ollendorff syndrome.